Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYV-101 in Refractory Lupus Nephritis
DRKS00034010Phase 2Recruiting
- Sponsor
- Kyverna Therapeutics
- Start
- Jul 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of mivocabtagene autoleucel in lupus nephritis (LN), systemic lupus erythematosus (SLE), sponsored by Kyverna Therapeutics. Started Jul 2024; status: recruiting.
02
Drugs
mivocabtagene autoleucel
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on DRKS00034010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00034010.